Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

Prospective Validation of the Movement Disorder Society Prodromal Multiple System Atrophy Criteria in Pure Autonomic Failure.

Movement disorders : official journal of the Movement Disorder Society·2026

Same author

Natural history and 12-month progression of multiple system atrophy in a Chinese cohort.

BMC neurology·2026

Same author

Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice.

Movement disorders clinical practice·2026

Same author

Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial.

The Lancet. Neurology·2026

Same author

Cognitive Trajectories from Preclinical Alzheimer's Disease to Dementia.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Is black carbon associated with cardiovascular and cancer mortality? Evidence from the Malmö Diet and Cancer Cohort.

Global health action·2026

Search research articles

Related Experiment Video

Updated: Sep 20, 2025

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

Disease Progression in Multiple System Atrophy-Novel Modeling Framework and Predictive Factors.

Line Kühnel^1,2, Lars Lau Raket^1,3, Daniel Oudin Åström¹

¹H. Lundbeck A/S, Copenhagen, Denmark.

Movement Disorders : Official Journal of the Movement Disorder Society

|June 7, 2022

Summary

A new model tracks Multiple System Atrophy (MSA) progression, predicting patient stages and survival. MSA-parkinsonian type shows faster progression, impacting disease course and treatment strategies.

Keywords:

disease progression motor subtype multiple system atrophy multivariate nonlinear mixed-effects models neurodegenerative disease

More Related Videos

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

Related Experiment Videos

Last Updated: Sep 20, 2025

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

Area of Science:

Neurodegenerative diseases
Biostatistics
Clinical progression modeling

Background:

Multiple system atrophy (MSA) is a rare, aggressive neurodegenerative disease with a rapid course, typically leading to death within 6-10 years.
Understanding MSA disease progression and influencing factors is critical due to its rapid evolution.

Purpose of the Study:

To develop a novel disease-progression model for Multiple System Atrophy (MSA).
To estimate a population-level MSA progression trajectory.
To predict patient-specific continuous disease stages.

Main Methods:

A disease-progression model was developed using data from the European MSA natural history study.
The model estimated population-level progression trajectories for Unified MSA Rating Scale and Unified Parkinson's Disease Rating Scale subscales.
Validation involved analyses based on reported anchor points, and the impact of MSA subtype on progression rate was assessed.

Main Results:

The predicted disease continuum spanned approximately 6 years, with an average of 51 months from global disability score 0 to 4.
Predicted continuous disease stages correlated with symptom onset time and predicted survival.
MSA motor subtype significantly affected progression, with MSA-parkinsonian (MSA-P) patients exhibiting accelerated progression.

Conclusions:

The novel modeling framework offers a new approach to analyzing and interpreting MSA progression.
It provides opportunities to investigate covariate effects on progression rates.
The model offers well-founded predictions of patient-level future progressions.